Phase II randomized clinical trial conducted in Hamilton, Ontario to recruit patients exposed to asbestos and affected with asbestosis or asbestos-related benign pleural disease and therefore at increased risk of mesothelioma. We will explore the potential for a non-toxic phytocomplex extract from the artichoke plant as a chemoprevention agent. We will also monitor the potential toxicity of this plant extract as well.
Impact
The primary objective of this phase II clinical trial is to determine whether Artichoke WPC (dried artichoke extract) has sufficient biological activity in conditions related to asbestos exposure and risk of mesothelioma to warrant more extensive development in phase III trials. If the trial provides evidence of a sufficient biological activity, the study has the potential to be further developed as both a prevention study on healthy individuals and a therapy in patients with mesothelioma
Student Experience
No student involvement.
Countries
Canada, Italy
Impact
Research
Institutional Partner(s)
Community Partner(s)
Industry Partner(s)
ABOCA S.p.A. Societa Agricola
Key Outcomes
Publications, Patents
Sponsorship
Private Foreign
Sponsorship Details
ABOCA S.p.A. Societa Agricola located in Italy, has provided funds and the product for this trial.
